Tumor Lysis Syndrome
10
0
0
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
20.0%
2 terminated out of 10 trials
80.0%
-6.5% vs benchmark
50%
5 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Elitek (Rasburicase) Immuno-Monitoring Study
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Fasturtec TLS Treatment / Prophylysis